Fig. 2.

Preferential affinities of somatostatin, somatostatin analogs octreotide and lanreotide, and the new multi-receptor ligand somatostatin analog pasireotide for the five known somatostatin receptor subtypes sst1–sst5. Ref. [10] (adapted from Petersenn S, Endocrine Updates, 2011 with kind permission from Springer Science+Business Media B.V.)